Search

ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).

Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.

Annual meeting on Oligonucleotide and Peptide Therapeutics in Boston, MA, U.S.

Annual meeting of the Association for Research in Vision and Ophthalmology in Denver, CO, U.S.

ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.

ProQR's participation in the SVB Leerink 2022 Global Healthcare Conference.

During this webcast ProQR leadership will highlight key advancements from its clinical-stage pipeline and Axiomer® RNA editing platform.

ProQR's participation in the Evercore ISI 4th Annual HealthCONx Conference.

ProQR's participation in the Stifel 2021 Virtual Healthcare Conference.

The Eye on the Future Forum (EFF) is a platform hosted by ProQR on innovative clinical development approaches for genetic eye diseases. This Fall Summit will explore the Science of RNA Therapies.